Since the July FDA advisory committee vote, nearly every conversation about peptide regulation — including most of what I've published on this site — has centered on one agency and one question: will the FDA add these substances to the 503A bulks list, and when? That's the right long-term question. It is not the question that determines what happens to a clinic, or a prescriber, or a patient's continuity of care this year.
That question belongs to a different set of regulators entirely: the state boards. The board of medicine (in Georgia, the Composite Medical Board; in Tennessee, the Board of Medical Examiners and the Board of Osteopathic Examination) licenses every physician. The state board of pharmacy licenses every pharmacy that dispenses into the state — including out-of-state compounders shipping in. These bodies do not wait for federal rulemaking, they do not operate on the FDA's timeline, and their actions land on individuals, by name.
This is not hypothetical. Two states have already moved.
Ohio. The Ohio Board of Pharmacy has pursued summary suspension actions involving compounded peptides — the substances named in reporting include BPC-157, a CJC/Ipamorelin combination, and Kisspeptin. A summary suspension is the board's emergency tool: practice stops first, and the hearing comes after. No proposed rule, no comment period, no year of lead time. Legal counsel who defend compounding pharmacies have been writing all summer about boards of pharmacy stepping up inspections of peptide compounding specifically.
Alabama. Effective May 26, 2026, the Alabama Board of Medical Examiners adopted a rule barring physicians from prescribing non-FDA-approved peptides outright — regardless of consent forms, regardless of sourcing, and without waiting for the FDA to finish anything. When that rule took effect, we removed Alabama from our own telemedicine footprint the same season, because a signed consent form provides zero protection against a state rule that simply prohibits the prescription. A clinic still advertising peptide telehealth into Alabama today is advertising something its prescribers cannot lawfully do.
Georgia — added August 18, 2026. When this piece was published on August 14, it argued that Georgia's board could move faster than the FDA. That framing is now understated, and I would rather correct it than leave it. Georgia's board has moved, and it is doing so physically: the Composite Medical Board is conducting unannounced site inspections of med spas, IV hydration clinics, and wellness practices, in rural and urban areas alike. Reporting on the findings describes medical services delivered by unlicensed workers, medications compounded unlawfully, staff practicing outside their training, treatment administered without the required medical examination, absent physician oversight, failure to track adverse events, and chiropractors offering testosterone and weight-loss treatments in a state whose chiropractic scope statute does not authorize prescribing or injecting. The Board has said it intends to keep inspecting and to seek legislation imposing registration requirements on med spas and IV facilities. Read alongside the Board's May 7, 2026 IV therapy position statement, this is the fastest-moving regulatory story in our market — and it is happening at street level, not in the Federal Register. The license-by-license breakdown is here: Who is allowed to inject you?
What the boards can actually do.
| Regulator | Typical timeline | What it can reach |
|---|---|---|
| FDA rulemaking | 12–24 months; final action on the July peptides unlikely before late 2027 | What substances 503A pharmacies may compound, nationally |
| FDA / FTC advertising enforcement | Warning letters in batches — 30 in a single day in March 2026 | Marketing claims: "clinically proven," "incredibly safe," unsubstantiated benefits |
| State board of medicine | Weeks to months; summary suspension available in emergencies | The individual physician's license — standard of care, informed consent, telehealth conduct |
| State board of pharmacy | Weeks to months; inspections ongoing now | Any pharmacy dispensing into the state, including out-of-state compounders |
Three things about board authority are worth understanding as a patient:
- Standard of care travels with the license, not the office. In both Georgia and Tennessee, a physician treating a patient by telehealth is held to the same standard of care as in an in-person encounter, and generally must hold a license in the state where the patient sits. There is no lighter "telehealth standard" for prescribing.
- Boards act on conduct, not just substances. Even where a substance's status is unsettled, a board can examine whether there was a real evaluation, a real indication, real informed consent, and real follow-up — or whether a subscription checkout page stood in for all four.
- Nothing in the July vote protects anyone. An advisory committee recommendation has no legal effect. It does not change what pharmacies may compound, and it certainly does not bind a state board evaluating a licensee's judgment.
Why the telehealth subscription model is the most exposed.
Attorneys analyzing the national telehealth-prescribing platforms — the model where you fill out an intake form, are matched with a prescriber you may never meet on video, and receive a monthly peptide subscription — have flagged exactly this structure as the pressure point. The recurring features of that model map directly onto what boards examine:
- A prescriber licensed somewhere, prescribing into states where the clinical relationship is thinnest;
- No named physician anywhere on the website — so no one visibly accountable to any board;
- Protocol menus fixed before anyone has seen your labs;
- And, in several cases we track in this market, substances that are not lawful to compound for humans at all — sold alongside ones that are.
When enforcement comes to this market — and Ohio suggests the question is when — it will not arrive as a press release about the FDA. It will arrive as a board action against a license, and the patients of that practice will find out when the refills stop. That is the continuity-of-care risk nobody's marketing mentions.
Three questions that take five minutes
- "Is the prescribing physician licensed in my state, and what is their name?" In Georgia, verify at the Composite Medical Board's license lookup; in Tennessee, at the Department of Health's license verification portal. If the website won't give you a name to look up, that is the answer.
- "Which pharmacy compounds this, and is it licensed to dispense into my state?" State boards of pharmacy license out-of-state compounders — this is checkable, and a real clinic will answer without friction.
- "If a state board or the FDA changes the status of my peptide, what happens to my protocol?" A clinic that has thought about this has a written answer. We publish ours: the protocol is rebuilt around lawful alternatives, with the reasoning documented — because the plan was never a single molecule.
Where Limitless stands.
I hold my license where my patients are — Georgia and Tennessee — and my name is on every page of this site, every protocol, and every prescription. We source exclusively through licensed 503A compounding pharmacies with per-lot certificates of analysis, prescribe individual substances for stated indications rather than pre-named blends, and put the regulatory uncertainty in writing before anyone starts therapy. When Alabama closed its door, we stopped offering telemedicine there rather than pretending a consent form could hold it open. None of that is heroic. It is what having a license worth protecting looks like — and it is precisely the layer that a checkout-page subscription cannot offer you.
The FDA question — what gets added to the 503A list, and when — matters, and we track it more closely than anyone in this market. But if you are choosing a clinic this year, the board question is the sharper screen. Ask for the name. Look it up. It takes five minutes, and it tells you almost everything.